Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ypsomed Holding AGYPHDF 94 3-Year EBITDA Growth Rate is 32.80% as of Mar. 2026, which is 176% above its 10-year median of 11.90. GuruFocus rates YPHDF with a GF Score™ of 94/100 and a GF Value™ of $461.36 (Fairly Valued). The stock has 5 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Ypsomed Holding AG ranks better than 79.19% on this metric.
During the past 12 months, Ypsomed Holding AG's average EBITDA Per Share Growth Rate was 71.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 32.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 32.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ypsomed Holding AG was 51.60% per year. The lowest was -90.40% per year. And the median was 11.90% per year.
Ypsomed Holding AG (OTCPK:YPHDF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ypsomed Holding AG 3-Year EBITDA Growth Rate Related Terms
YPHDF vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's 3-Year EBITDA Growth Rate falls into.
Ypsomed Holding AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 32.80% mean?
Ypsomed Holding AG (YPHDF) has a 3-Year EBITDA Growth Rate of 32.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ypsomed Holding AG and its competitors. This is 176% above median its historical median of 11.90. According to the industry distribution chart, Ypsomed Holding AG ranks #144 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Ypsomed Holding AG's 3-Year EBITDA Growth Rate too high?
Ypsomed Holding AG's current 3-Year EBITDA Growth Rate of 32.80% is 176% above median its 10-year median of 11.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Ypsomed Holding AG's value of 32.80% is 300% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #144 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ypsomed Holding AG has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #144 out of 692 companies for 3-Year EBITDA Growth Rate. This places Ypsomed Holding AG in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Ypsomed Holding AG's value of 32.80% is 300% above this benchmark. While the company's 10-year median is 11.90 vs. the industry median of 8.20, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current 3-Year EBITDA Growth Rate of 32.80% is 300% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current 3-Year EBITDA Growth Rate is 32.80%, which is 176% above median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (YPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $461.36, compared to a current price of $476.49 — trading 3.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 32.80%, which is 176% above median its 10-year median of 11.90 and 300% above the Medical Devices & Instruments industry median of 8.20. Ypsomed Holding AG's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ypsomed Holding AG (YPHDF), the current 3-Year EBITDA Growth Rate is 32.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (YPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be overvalued.
The current stock price of $476.49 is trading 3.3% above its estimated GF Value™ of $461.36.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for YPHDF:
3-Year EBITDA Growth Rate: 32.80% (176% above median its 10-year median of 11.90)
GF Value™: $461.36 vs. price of $476.49 (3.3% above fair value)
Industry Position: 300% above the Medical Devices & Instruments median (#144 of 692)
No single metric tells the full story. See the YPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
94GF Score
Get the complete analysis for YPHDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YPHDF has been successfully added to your 
